1123 AZ COVID vaccine data

Product Development

Less is more: If AZ’s low-dose COVID-19 vaccine regimen works better, more people will benefit

Plus what the results mean for the next viral vector vaccine slated to read out: JNJ-78436735 from J&J

Nov 24, 2020 | 1:40 AM GMT

Regardless of why the full-dose regimen of AstraZeneca’s COVID-19 vaccine performed worse than a partial-dose regimen, better efficacy with less vaccine means supplies will stretch farther. 

On Monday, AZD1222 from AstraZeneca plc (LSE:AZN; NASDAQ:AZN) and partner University of Oxford became the third COVID-19 vaccine to meet FDA’s threshold for efficacy, behind mRNA-1273 from Moderna Inc. (NASDAQ:MRNA) and BNT162b2

Read the full 988 word article

How to gain access

Continue reading with a
two-week free trial.